Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for teens with rare obesity: weekly shot shows promise

NCT ID NCT07302802

Disease control Sponsor: Prof. Dr. Martin Wabitsch Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a once-weekly injection of semaglutide (2.4 mg) can help teenagers with monogenic obesity lose weight and feel better. About 70 teens aged 12 to 20 will take the drug along with diet and exercise changes for 68 weeks. The main goal is to see if at least 10% of their body mass index (BMI) drops, and to track changes in hunger, body composition, mood, and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged ≥12 to \<21 years diagnosed with monogenic obesity, who agreed on treatment with semaglutide, are eligible for study participation.

Ages

12 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Treatment with semaglutide as prescribed in routine clinical practice according to summary of product characteristics. 2. Informed consent of the patient, their parents, or legally acceptable representative (LAR) of participant and adolescent assent, as age-appropriate. 3. Age at time of signing informed consent: ≥12 to \<21 years. 4. BMI ≥95th percentile as defined on sex- and age-specific BMI growth charts (CDC.gov) 5. Body weight of \>60 kg. 6. Diagnosis of monogenic obesity by a Clinical Laboratory Improvement Amendments (CLIA)/ College of American Pathologists (CAP)/International Organisation for Standardization (ISO) 1518-certified laboratory using ACMG criteria as pathogenic (P), likely pathogenic (LP) and variant of uncertain significance (VUS). Exclusion Criteria: 1. Participation in any interventional clinical trials at the time of enrolment. 2. Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice) 3. Hypersensitivity to the active substance or to any of the excipients listed: * Disodium phosphate, dihydrate * Propylene glycol * Phenol * Hydrochloric acid (for pH adjustment) * Sodium hydroxide (for pH adjustment) * Water for injection 4. The safety and efficacy of Wegovy have not been investigated in patients: * treated with other products for weight management, * with type 1 diabetes, * with severe renal impairment (see section 4.2), * with severe hepatic impairment (see section 4.2), * with congestive heart failure New York Heart Association (NYHA) class IV. Use in these patients is not recommended

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monogenic obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monogenic obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique-Hôpitaux de Paris (AP-HP), Trousseau Hospital Paris, Pediatric Nutrition Department

    NOT_YET_RECRUITING

    Paris, France

  • Departments of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid

    NOT_YET_RECRUITING

    Madrid, 28009, Spain

  • Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Centre

    RECRUITING

    Ulm, 89075, Germany

  • Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin

    NOT_YET_RECRUITING

    Berlin, 13353, Germany

  • University Hospital for Children and Adolescents, Center for Pediatric Research, Medical Faculty, University of Leipzig

    NOT_YET_RECRUITING

    Leipzig, 04103, Germany

  • University Medical Center Rotterdam, Erasmus MC-Sophia Children's Hospital

    NOT_YET_RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Wellcome-MRC Institute of Metabolic Science and NIHR Cambridge Biomedical Research Centre

    NOT_YET_RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.